ESR1 and breast carcinoma: Over the past decade, TFF3 has emerged as a promising therapeutic target due to its promotory role in cancer progression, including colorectal, hepatocellular, lung, pancreatic, prostate, cervical, endometrial, and ER+ mammary carcinomas [9, 10, 12–21].